News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TransCelerate BioPharma Grows Industry Collaboration



9/14/2017 7:17:47 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

PHILADELPHIA--(BUSINESS WIRE)--TransCelerate BioPharma Inc. announces the addition of Novartis (NYSE: NVS) to the biopharmaceutical non-profit organization, growing the consortium to 19 biopharmaceutical companies. In addition, TransCelerate membership have elected Elliott Levy, MD, Senior Vice President, Global Development at Amgen as the new Chair of the Board of the Directors and David Nicholson, PhD, Executive Vice President, and Chief R&D Officer at Allergan, will assume the Vice Chair role.

TransCelerate CEO, Dalvir Gill, PhD, states, “Our membership is comprised of prominent biopharmaceutical companies that are in active pursuit of solutions that will help simplify and accelerate the research and development of innovative high-quality drugs. The addition of Novartis will further advance the adoption of tangible improvements that foster more efficient and accessible clinical research environments for key stakeholders.”

Over the last few years, we have observed TransCelerate making significant progress on tackling opportunities within research and development,” said Badhri Srinivasan, Head, Global Development Operations at Novartis and newly appointed member of the TransCelerate Board of Directors. “Novartis has been at the forefront of improving drug development efficiency, and by joining TransCelerate, we can both contribute to and benefit from the collaborative power of this industry-wide organization.”

Dr. Gill went on to note, “I’d like to congratulate Dr. Elliott Levy and Dr. David Nicholson on being elected to their new leadership positions within our organization. We are very excited to work together as we continue to realize improvements across the R&D ecosystem. I also want to thank Dr. Iris Loew-Friedrich for her commitment to TransCelerate’s strategy and efforts as Chair of the Board for the last two years. Throughout her career, Iris has been a champion for innovative solutions that focus on better understanding and enriching the patient experience. TransCelerate has greatly benefitted from her leadership and unwavering support.”

TransCelerate’s former Chair of the Board, Dr. Iris Loew-Friedrich, Executive Vice President, and Chief Medical Officer at UCB said, "Novartis joining the organization demonstrates our industry’s growing recognition and demand for innovative and collaborative solutions that address the most complex matters related to drug research and development. It has been my honor to serve as Chair of the Board and am looking forward to TransCelerate’s growth in the years to come as I continue to serve on the Board.”

For more information on the new Chair and other board members, please visit the website: http://www.transceleratebiopharmainc.com/our-leadership/. Membership in TransCelerate is open to pharmaceutical and biotechnology companies with Research & Development operations. To see if your organization qualifies, read more information here.

About TransCelerate BioPharma, Inc.

TransCelerate BioPharma Inc. is a non-profit organization dedicated to improving the health of people around the world by simplifying and accelerating the research and development (R&D) of innovative new therapies. The organizations' mission is to collaborate across the global biopharmaceutical R&D community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high-quality delivery of new medicines. TransCelerate evolved from conversations at various forums for executive R&D leadership to discuss current issues facing the industry, and examine solutions for addressing common challenges. The founding member companies are AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, the Roche Group, and Sanofi. Additional members that have joined since the inception of TransCelerate include Allergan, Inc., Amgen, Astellas Pharma Inc., EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, Germany), Merck & Co., Inc., Novartis International AG, Novo Nordisk, Shionogi & Co., Ltd. and UCB.

Membership in TransCelerate is open to pharmaceutical and biotechnology companies with Research & Development operations. Executive offices are located in Philadelphia, PA. For more information, please visit http://www.transceleratebiopharmainc.com.

Follow us on Twitter: https://twitter.com/transcelerate

Reach us on LinkedIn: www.linkedin.com/company/transcelerate-biopharma-inc-

Media:
Bliss Integrated Communication
Vicky Aguiar, 212-584-5470
Vicky@blissintegrated.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES